SCHEMBL4886384

SCHEMBL4886384

CC(CCc1ccccc1)NC(=O)c1ccccc1C1CCN(CCN2C=COC(C3=CC=CC(=O)C3)=C2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.41
TSHR P16473 2/20 0.37
USP2 O75604 1/20 0.37
HTT P42858 4/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KMT2A Q03164 5/20 0.36
MEN1 O00255 3/20 0.36
MDM2 Q00987 1/20 0.36
ATM Q13315 1/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALOX15 P16050 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PRCP P42785 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4432781 0.88 NPFFR1 (0.36) POLBUSP2HTTALDH1A1HPGD
SCHEMBL4886308 0.87 PRCP (0.38) PRCP
SCHEMBL15808512 0.87 EPHX2 (0.37) TSHRHTTALDH1A1HPGDSMN1; SMN2
SCHEMBL4880934 0.86 UTS2R (0.38) POLBALDH1A1KMT2AMEN1
SCHEMBL4432414 0.86 ASAH1 (0.39) POLBTSHRHPGDSMN1; SMN2KMT2A
SCHEMBL4889118 0.85 SIGMAR1 (0.36) ALDH1A1KMT2AKDM4EPRCP
SCHEMBL4431342 0.85 PRCP (0.38) SMN1; SMN2MAPTPRCP
SCHEMBL4438087 0.84 UTS2R (0.43)
SCHEMBL4886094 0.84 OPRM1 (0.34) TSHRALDH1A1KMT2AMEN1KDM4E
SCHEMBL4430408 0.84 UTS2R (0.37) POLBALDH1A1HPGDL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US claimed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US claimed
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 POLB 4040/4885TSHR 527/4885USP2 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.